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An anti-TNF-α antibody mimetic to 
treat ocular inflammation
Hanieh Khalili1,2,3,*, Richard W. Lee2,4, Peng T. Khaw2, Steve Brocchini1,2, Andrew D. Dick2,4 & 
David A. Copland2,4,*
Infliximab is an antibody that neutralizes TNF-α and is used principally by systemic administration to 
treat many inflammatory disorders. We prepared the antibody mimetic Fab-PEG-Fab (FpFinfliximab) for 
direct intravitreal injection to assess whether such formulations have biological activity and potential 
utility for ocular use. FpFinfliximab was designed to address side effects caused by antibody degradation 
and the presence of the Fc region. Surface plasmon resonance analysis indicated that infliximab and 
FpFinfliximab maintained binding affinity for both human and murine recombinant TNF-α. No Fc mediated 
RPE cellular uptake was observed for FpFinfliximab. Both Infliximab and FpFinfliximab suppressed ocular 
inflammation by reducing the number of CD45+ infiltrate cells in the EAU mice after a single intravitreal 
injection at the onset of peak disease. These results offer an opportunity to develop and formulate for 
ocular use, FpF molecules designed for single and potentially multiple targets using bi-specific FpFs.
Uveitis is a CD4+ T-cell mediated, non-infectious inflammatory condition in the eye that can result in blindness1. 
Tumor necrosis factor (TNF-α ), is secreted by macrophages, T-cells other cell types including neurons and there 
are increased concentrations of TNF-α and soluble TNF-α receptors in the aqueous humor of non-infectious 
uveitis patients2,3. TNF-α plays a pivotal role in inflammatory responses and neutralizing TNF-α delivers a potent 
regulation of experimental autoimmune uveoretinitis (EAU)4.
Therapeutic antibodies that target TNF-α such as infliximab are widely used to treat inflammatory condi-
tions, e.g. rheumatoid arthritis5–7. Off-label use of these antibodies suggests they can be used to reduce ocular 
inflammation caused by uveitis8. However, systemic administration of anti-TNFα antibodies does carry risks of 
severe adverse reactions (e.g. activation of latent infection, hepatotoxicity, lupus) and is contraindicated in some 
patients9. High doses (e.g. 5 mg/kg)10 are necessary to achieve therapeutic levels within the eye. Whilst there 
is now significant evidence describing the clinical efficacy of anti-TNF therapies, in particular when delivered 
systemically for treatment of uveitis associated with systemic disorders (e.g. Behcet’s disease), there remains an 
unmet need to exploit the rapid onset of action of antibodies that target TNF-α through intravitreal (IVT) injec-
tion. This would permit the administration of higher and reproducible doses directly to the eye, allowing us to 
treat isolated intraocular inflammation without need for systemic therapies. Unfortunately, the IVT injection of 
antibodies such as infliximab that target TNF-α have been associated with elevation of inflammatory markers and 
increased retinotoxicity in uveitis patients11–15.
Experimental autoimmune uveitis (EAU) is a mouse model that displays a subacute and more clinically ful-
minant form of ocular inflammation4. The use of many animal models to evaluate the efficacy of therapeutic 
antibodies that are targeted to human proteins is often limited due to decreased affinity for the murine target, but 
also due to the formation of anti-drug antibodies. In the current study, we demonstrate that infliximab has strong 
binding affinity to both mouse and human TNF-α , and in vivo administration suppresses infiltration of inflam-
matory immune cells to the retina. The clinical potential of infliximab was validated using the EAU platform to 
provide the basis for us to then develop and evaluate an antibody mimetic termed Fab-PEG-Fab (FpF), compris-
ing Fab fragments derived from infliximab. The use of FpFinfliximab allowed a direct comparison with infliximab. 
Our results demonstrate that FpFinfliximab, which lacks the potentially immunogenic Fc region, is not taken up by 
retinal pigment epithelium (RPE) cells as is infliximab. FpFinfliximab maintains robust binding affinity to TNF-α but 
importantly is also efficacious in terms of suppressing the acute phase of inflammation in the EAU mouse model.
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Results
Intravitreal administration of Infliximab suppresses EAU. Infliximab is an IgG1, chimeric monoclo-
nal antibody developed to bind to human TNF-α to inhibit its interaction with TNF-receptors. It was not clear 
from the literature describing systemic use of infliximab in different preclinical models, whether it can bind to 
mouse TNF-α and therefore enable us to demonstrate efficacy in the EAU model16–18. Ocular administration 
of infliximab has been shown to provide significant retinal and corneal protection in an mouse model of alkali 
injury19, as well as modulating choroidal neovascularization and endotoxin-induced inflammation in rat and 
rabbit experimental models respectively20,21. In the current study we therefore sought to confirm the binding of 
infliximab to both murine (Fig. 1a) and human (Figure S1A) recombinant TNF-α by surface plasmon resonance 
(SPR) prior to conducting an in vivo assessment using the EAU model.
As in previous pre-clinical studies, we then utilised the highly susceptible B10.RIII mouse strain in which the 
immunising regimen produces consistent moderate disease severity22. Using topical endoscopic fundal imaging 
(TEFI)23,24, clinical changes which correlate with significant inflammatory cell tissue infiltrate are evident from 
around day 10 post immunization. During the acute period these are progressive changes that include a swollen 
optic nerve, peri-vascular infiltrate and vasculitis, vitritis and retinal detachment. These resolve by day 28 leaving 
a persistent chorioretinal inflammatory infiltrate for months23. In the current experiments, TEFI enabled us to 
screen and select experimental groups of mice that displayed early signs of disease onset, namely raised optic 
nerve or early vasculitis.
Groups of selected mice were treated on day 10 with a single intravitreal administration of infliximab (15 μ g/ 
eye) or control vehicle. The clinical appearance was assessed daily, and the retinal infiltrate examined and enu-
merated by flow cytometry at 96 hours following dose administration. Clinically at this time point, control treated 
mice display typical disease features with raised optic disc, vasculitis and choroidal lesions, whereas mice receiv-
ing infliximab only exhibited low grade disease (Fig. 1b,c). Flow cytometric analyses of the retinas of the inflixi-
mab mice on day 14 display significantly reduced CD45 positive infiltrate (Fig. 1d), reflecting reductions in CD4, 
CD8, CD11b and Ly6G positive populations (Figure S2A). Overall, there is a 55% reduction of the total CD45+ 
infiltrate (with 68%, 62%, 38% & 64% reductions in CD4, CD8, CD11b and Ly6G populations respectively) in 
mice receiving infliximab compared to control animals.
Synthesis of endotoxin-free infliximab mimetic, FpFInfliximab. An IgG antibody mimetic called an FpF 
(Fab-PEG-Fab) was then prepared using the Fabs from infliximab (FpFinfliximab) and reagent 1 (Fig. 2). The robust 
suppression of clinical disease evident following intravitreal administration of infliximab, provided the rationale 
to prepare and evaluate FpFinfliximab. The Fabs in both an IgG antibody and FpF are at each terminus of a flexible 
chain that is topologically similar (Fig. 2a,c)25. The bis-sulfone moieties in reagent 1 readily undergo elimination 
to the corresponding mono-sulfone moieties, depicted as PEG-di(mono-sulfone) 2 (Fig. 2b). Conjugation occurs 
by a sequence of addition-elimination reactions to insert a stable 3-carbon methylene bridge between the two 
thiols of an accessible disulfide bond in a Fab (Figure S3)26. Site-specific conjugation with the two cysteine thiols 
from the Fab disulfide occurs in the region where the Fab is normally bound to the hinge in an IgG antibody. The 
thiol ether bonds in the re-bridged disulfide are more stable than the original disulfide bond.
Using endotoxin free reagents and working under sterile conditions, FpFinfliximab was prepared (Fig. 3a). First, 
infliximab was proteolytically digested with immobilized papain in the presence of cysteine monohydrate (Fig. 3a, 
lane 2), before elution of the purified Fabinfliximab over protein A (lane 3). The Fc fragment appeared at a slightly 
higher molecular weight on SDS-PAGE than the Fabinfliximab due to glycosylation present on the CH2 domain of 
the Fc fragment. Fabinfliximab was then treated with dithiothreitol (DTT) to reduce the accessible disulfide (lane 4).
After removal of DTT by elution over a PD-10 column, the Fabinfliximab solution was incubated with PEG 
di(mono-sulfone) reagent 2 (0.9 equiv.) to obtain FpFinfliximab that was then purified by ion-exchange chromatog-
raphy (lanes 5–6), which was confirmed by silver stain (lane 7). No unconjugated Fabinfliximab or the intermediate, 
(mono-sulfone)-PEG-Fabinfliximab, were observed. The endotoxin levels of both the purified Fabinfliximab after prote-
olytic digestion of infliximab and the purified FpFinfliximab were less than 0.005 EU/mL (EndoZyme assay). There 
was no heavy-light chain dissociation or aggregation of the FpFinfliximab when stored at 4 °C for 480 days (lane 8).
FpFinfliximab displayed slower dissociation rate constant compared to infliximab. SPR analysis 
demonstrated FpFinfliximab displayed concentration dependent binding to human histidine-tag TNFα (Figure S1B). 
The kinetic rate constants and relative binding affinities (KD) to human TNF-α were calculated using a 1:1 bind-
ing model ratio, showing that FpFinfliximab and infliximab share similar KD values (Fig. 3c). While the dissociation 
(kd) rate constants was approximately 5 times slower in FpFinfliximab compared to infliximab, association rate con-
stant (ka) appeared to be faster in infliximab. This is consistent for FpFs25 and other bivalent mimetics27 that have 
been evaluated by SPR. The slower dissociation rate constant suggested a tighter interaction between FpFs and 
TNFα , and potentially improved therapeutic efficacy for FpFinfliximab. The SPR analysis confirmed FpFinfliximab bind-
ing to murine TNF-α and warranted an in vivo assessment starting at a concentration of 100 μ g/mL FpFinfliximab 
(Fig. 3b).
In vitro evaluation of Fc mediated uptake. Antibody uptake into the retinal pigment epithelium (RPE)28 
can occur via neonatal Fc-receptors expressed in RPE cells29,30. Uptake of infliximab and FpFinfliximab were assessed 
in vitro using a murine B6RPE-07 cell line31 in which cell cultures exhibit cobblestone-like morphology similar 
to primary mouse RPE cultures. The cells also express RPE markers, tight junction and adhesion molecules, and 
show polarized phenotype when cultured in collagen-coated membrane31 and have been used as an in vitro RPE 
model in many recent functional studies32–35. We used RT-qPCR to measure Fcgrt mRNA from samples of cul-
tured B6RPE-07 cells, to confirm expression of the transmembrane domain of the neonatal Fc receptor in this cell 
line (Fig. S4). Confluent RPE cell monolayers were treated separately with 250 μ g/ml of each molecule, and cell 
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lysates examined for presence of anti-human IgG Fab fragment. Western blot analysis indicated that intracellular 
infliximab was detectable in murine B6RPE-07 cells at 4 and more strongly by 24 hrs. In contrast, incubation of 
FpFinfliximab did not result in any detectable Fab protein indicating no intracellular uptake (Fig. 3d).
FpFInfliximab is efficacious in EAU. Using the same local administration regimen as described for infliximab, 
immunized mice displaying the initial signs of clinical disease were selected for treatment groups on day 10, with 
animals receiving a single intravitreal administration of FpFinfliximab (15 μ g/eye) or control vehicle. In eyes receiv-
ing FpFinfliximab only the initial disease changes to the optic disc with some early signs of vasculitis were evident 
contrasting the expected inflammatory changes and disease severity observed in EAU controls (Fig. 4a,b). At day 
Figure 1. Local administration of infliximab suppresses EAU. (a) Graph detailing the Surface Plasmon 
Resonance (SPR) binding analysis, confirming that infliximab can bind to murine TNF-α using a NTA 
chip. (b–d) Mice were immunized for EAU and eyes monitored using TEFI from day 10 onward to select 
experimental mice displaying clinically evident disease. Groups of mice were injected via intravitreal route 
with 15 μ g infliximab or vehicle control (EAU) on day 10. Eyes were enucleated on day 14, and retinal 
infiltrate characterized and quantified; (b) Representative TEFI images and (c) combined total disease scores 
demonstrating the difference in clinical disease progression between treatment groups. In EAU control eyes 
typical disease progression with signs of raised optic disc, vasculitis and severe inflammation; In infliximab 
treated eyes, only raised optic disc and initial signs of vasculitis are evident. (d) Graph showing total CD45+ 
infiltrate numbers from individual eyes. *P < 0.05, **P < 0.005, ***P < 0.0005; Data presented as means ± SEM, 
and representative of two independent experiments.
www.nature.com/scientificreports/
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14, flow cytometric assessment of retinal infiltrate demonstrates an equally significant reduction of CD45+ infil-
trate in mice receiving FpFinfliximab treatment (Figs 4c and S2B) as compared to infliximab. Overall, there is a 74% 
reduction of the total CD45+ infiltrate, comprising 69%, 62%, 74% and 82% reductions in CD4, CD8, CD11b and 
Ly6G populations respectively in mice treated with FpFinfliximab compared to control animals.
Figure 2. Schematic of Fab-PEG-Fab synthesis from whole IgG. (a) Representation of infliximab, an IgG1 
with two Fabs that are linked together through the hinge as if each Fab is linked at the end of a linear molecule. 
Proteolytical digestion of IgG1 yield the Fabs fragment which are then treated with DTT and then linked to 
each end of PEG di(mono-sulfone) reagent 2 to make FpF, (b) PEG di(mono-sulfone) reagent 2 is synthesised 
from PEG di(bis-sulfone) reagent 1 through elimination of toluene sulfinic acid anion (c) The FpFinfliximab is 
synthesized in a way to compare directly to the starting infliximab. This strategy is applicable on different kind 
of monoclonal IgGs such as human, humanised and chimeric IgGs.
Figure 3. FpFinfliximab preparations: assessment of stability, affinity & intracellular uptake. (a) Representative 
Coomassie and silver-stained SDS-PAGE demonstrate the synthesis steps and protein size modifications 
involved in synthesis of FpFinfliximab from whole infliximab (lanes 1–7). FpFinfliximab stored at 4 °C for 480 days 
did not display dissociation from the PEG linker or aggregate formation (lane 8), (b) SPR binding analysis 
demonstrates that FpFinfliximab binds murine TNF-α using NTA chip, (c) Kinetic affinity (KD) and rate constants 
(ka, kd) for infliximab and FpFinfliximab to recombinant human TNF-α . FpF has similar binding affinity to full IgG, 
but the dissociation rate constants are 5× slower for FpFinfliximab, (d) Whole cell lysates prepared from B6RPE-07  
cells treated with infliximab or FpFinfliximab, for 4 & 24 hrs, were probed and the presence of the molecules 
detected using anti-human IgG Fab. As a negative control, cells were incubated with media alone; and as a 
positive control preparations of either molecule were applied to the lane.
www.nature.com/scientificreports/
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Discussion
There is an ever-growing need to develop targeted therapies for use in the eye. Ideally, therapies are needed that 
are directed to multiple specific targets. We are developing recombinant-conjugation strategies focused on the 
development of multifunctional and bispecific proteins that are difficult to make entirely by recombinant means 
alone. For organ specific delivery such as to the eye, there is also a need to ensure new biologically based med-
icines remain stable throughout the planned duration of action. In this study we started with an anti-TNF-α 
FpF to determine its ability to achieve biological efficacy in terms of suppressing retinal infiltrate in a clinically 
relevant, aggressive model of ocular inflammation. TNF-α is involved in the pathogenesis of inflammation, and 
it has also important roles in progression of undesirable angiogenesis in the eye in the neovascular age-related 
macular degeneration (AMD) and proliferative vitreoretinopathy diseases36,37. In this proof-of-concept study we 
demonstrate for the first time that infliximab suppressed the acute phase of inflammation by reducing the number 
of CD45+ infiltrate cells in the eyes of the EAU mice. In vivo, infliximab and FpFinfliximab are equally efficacious 
as determined by clinical observation while significantly suppressing the infiltration of leukocytes into the retina 
during peak EAU. This aspect of the study was required before FpF molecules directed to multiple targets can be 
evaluated.
Figure 4. FpFinfliximab is efficacious in suppressing disease in vivo. Mice were immunized for EAU and eyes 
monitored using TEFI from day 10 onward to select experimental mice displaying clinically evident disease. 
Groups of mice received an intravitreal injection of 15 μ g FpFinfliximab or vehicle control (EAU) on day 10. Eyes 
were enucleated on day 14, and retinal infiltrate characterized and quantified. Representative TEFI images (a) 
and combined disease scores (b) demonstrating the difference in clinical disease progression between treatment 
groups. Graph showing total CD45+ infiltrate numbers from individual eyes (c). *P < 0.05, **P < 0.005, 
***P < 0.0005; Data presented as means ± SEM, and representative of two independent experiments.
www.nature.com/scientificreports/
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FpFinfliximab synthesis from Fabs obtained by the enzymatic digestion of infliximab allowed the direct compari-
son of infliximab and FpFinfliximab. The flexible hydrophilic PEG scaffold replaced the infliximab Fc. The inflamma-
tory reaction after IVT injection of infliximab may be due to Fc related effects or due to antibody degradation or 
aggregation38. An FpF cannot cause localised inflammatory reactions due to the antibody Fc effector functions, 
which is important when considering treatments for an acute inflammatory condition such as uveitis. Antibody 
Fc mediated recycling that prolongs the duration of action during systemic use is not critical for ocular pharma-
cokinetics39 and may to some extent remove antibodies from within the eye30,40–43.
Since the Fab has an accessible disulfide near the hinge region, each Fab in an FpF is conjugated in essentially 
the same region that native Fabs are bound to the hinge region in IgG antibodies. The thiol-ether bonds of a 
re-bridged disulfide are more stable than the starting disulfide. The PEG scaffold is more stable than the single 
polypeptide chains of the IgG hinge, which are susceptible to cleavage reactions44,45, and the PEG would reduce 
the propensity for aggregation46,47 compared to an IgG. It is thought that the potential for increased stability of 
FpFinfliximab will provide opportunities to make easier-to-use high concentration formulations for direct intravit-
real ocular administration than is possible with IgG antibodies. This also raises the possibility of a requirement 
for less frequent injections compared to the standard antibody.
As TNF-α is a non-covalent trimer in circulation, it is not possible to maintain the trimeric structure of 
immobilised TNF-α after the regeneration step required for each SPR cycle to remove bound antibody. Since 
more realistic and comparative results are expected when the ligand, rather than the antibody, is immobilised 
onto a sensor chip48 we used histidine-tagged TNF-α for immobilisation onto a metal affinity chip (nitrilotriacetic 
acid; NTA). Each regeneration cycle caused removal of the TNF-α , but it was possible to obtain reproducible 
results by re-immobilising the same amount of TNF-α at the beginning of each SPR sample cycle.
Infliximab and FpFinfliximab both displayed binding to mouse TNF-α at high concentration. Binding of both 
infliximab and FpFinfliximab to human TNF-α was also observed, although binding was achieved at lower concen-
trations than with mouse. Binding of infliximab to mouse TNF-α was important to establish because there have 
been conflicting observations about infliximab’s binding with mouse TNF-α 16,49. Although the concentrations 
needed for binding to mouse TNF-α were higher than for human TNF-α , this level of binding was sufficient to 
evaluate anti-TNF-α molecules in the EAU model. The binding kinetics suggested that FpFinfliximab has compara-
ble affinity to infliximab, but slower association and dissociation rates. Slower association rates may be important 
in the design of new high affinity therapies that display decreased off-target effect. Slower dissociation rates may 
also be important to ensure that once bound to a ligand, an antibody does not in effect become a slow releasing 
depot for that ligand. Certainly there are applications were a decreased dissociation rate may be a viable strategy 
to increase efficacy by increasing the residence time within the target organ or tissue50. A potential disadvantage 
of decreased dissociation rates would be if a target cell surface receptor had agonist function.
The outer blood-retinal barrier, located between the choroid/Bruch’s membrane, exterior to the sub-retinal 
space and neural retina is formed by the retinal pigment epithelium (RPE), a cell monolayer interconnected by 
tight junctions. As a selective barrier, the RPE permits intraocular migration of leukocytes as well as a variety 
of physiological functions including the phagocytosis of shed photoreceptor outer segments and transport of 
molecules to and from the retina51,52. Recent data shows that therapeutic anti-VEGF mAbs (bevacizumab and 
afilbercept) can be transported intracellularly across RPE cells, implicating these cells as important protagonists 
in the clearance of antibodies from the sub-retinal space into the choroid28. Uptake in the RPE is a general feature 
of Fc-fragment containing molecules such as IgG28, via Fc-receptors expressed in RPE cells29,30. Using in vitro 
RPE cells, no sub-retinal uptake was observed for FpFinfliximab. The avoidance of RPE uptake and uptake to other 
cell types such as retinal endothelium53 could be important to minimize toxicity for longer acting dosage forms 
of biologics.
In summary, we have demonstrated that both infliximab and FpFinfliximab suppress intraocular inflammation 
by reducing the number of CD45+ infiltrate cells in the EAU mice model. Clinically, both molecules appeared to 
be equally effective in modulating the acute inflammatory response that characterizes EAU. FpFinfliximab displayed 
similar binding affinity (KD) with slower association and dissociation rates compared to infliximab. There was no 
Fc mediated RPE cellular uptake of FpFinfliximab. These characteristics along with a greater potential for FpF stabil-
ity are being further investigated to determine potential clinical advantages in developing new treatments using 
the FpF approach that can bind to two different targets.
Materials and Methods
Reagents. Complete medium consisted of Dulbecco’s modified Eagle’s medium(DMEM) supplemented with 
10% heat inactivated fetal calf serum, 100 U/ml penicillin–streptomycin, 2 mmol/l L-glutamine, 1 mmol/l sodium 
pyruvate and 5 × 10−5 mol/l 2-mercaptoethanol (all from Life Technologies, UK). For FpFinfliximab synthesis, prepa-
rations of infliximab (Remicade®; Janssen Biotech Inc., USA) were used as starting material. Human RBP-3161–180 
peptide (SGIPYIISYLHPGNTILHVD) was obtained from Severn Biotech (Kidderminster, UK). Peptide purity 
was determined by HPLC. Peptide preparations were aliquoted and stored at − 80 °C.
Mice. B10.RIII breeding colony was established in Animal service unit of University of Bristol. All mice were 
housed under specific pathogen-free conditions with continuously available food and water. The mice were 
aged between 6 and 8 weeks. Treatment of animals conformed to the Association for Research in Vision and 
Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. The methods were carried 
out in accordance with the approved University of Bristol institutional guidelines and all experimental protocols 
under a Home Office Project Licence 30/3281 were approved by the University of Bristol Ethical Review Group.
FpFInfliximab synthesis. Using endotoxin (ET) -free glassware and buffers, Fabinfliximab fragments were first 
obtained by enzymatic digestion of infliximab using immobilized papain as described previously25. Purified 
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Fabinfliximab was isolated from the digestion mixture using ET-free protein A midi kit (Generon, Maidenhead, UK) 
according to the manufacturer’s instructions. The endotoxin level of purified Fabinflix preparations was less than 
0.005 EU/mL as determined using EndoZyme assay.
Under sterile conditions, Fabinfliximab (2.4 mg/mL, 6.0 mg in 2.5 mL PBS, pH 7.3) was incubated with dithio-
threitol (DTT) (1.0 mg/mL, 2.5 mg) at ambient temperature without shaking for 30 min. DTT was removed by 
elution over a new PD-10 column, and the protein was buffer exchanged into the conjugation buffer (20 mM 
sodium phosphate, 10 mM EDTA, pH 7.4). PEG-di(mono-sulfone) 2 (0.9 eq, 10 kDa)25 was added (1.08 mg) to 
the reduced Fabinfliximab solution (6.0 mg in 3.3 mL). The endotoxin level of the PEG reagent was determined to be 
less than 0.005 EU/mL. The solution was incubated at ambient temperature for approximately 3 h without shak-
ing while maintaining sterility. FpFinfliximab was purified using a single step HiTrap Macrocap SP cation exchange 
column (IEC-Macrocap SP, 5.0 mL). The IEC-Macrocap SP column was first washed with NaOH (1 M) and then 
ET free water before sample loading. After sample loading, the column was first eluted with 100% acetate buffer 
A for 10 min followed by a 30 min linear gradient using 100% acetate buffer B containing 1.0 M NaCl with a 
flow-rate of 1.5 mL/min. Fractions (1.5 mL) were analysed by SDS-PAGE and the FpFinfliximab fractions pooled. 
Using viva-spin (Turbo 15, MW cut off 30 kDa), the FpFinfliximab was concentrated to 4.0 mg/mL in a total volume 
of 0.2 mL. The concentration of the purified FpFinfliximab was calculated by micro BCA assay using infliximab as 
standard. The endotoxin level of the concentrated FpFinfliximab was determined to be less than 0.005 EU/mL 
using the EndoZyme assay according to manufacturer’s instructions (Hyglos, Munich, Germany).
Surface Plasmon Resonance (SPR) Binding studies. Sensor chip NTA (nitrilotriacetic acid) is made 
of carboxymethylated dextran which is covalently immobilised with NTA. The surface of sensor chip NTA was 
first activated with nickel (Ni+2) solution to create the nickel chelated NTA group which allowed capture of 
histidine-tagged TNFα . Samples (FpFinfliximab or infliximab) were passed over the surface and the binding kinet-
ics were determined. Between runs, the NTA surface was regenerated with EDTA solution to refresh the sensor 
chip for a new analysis cycle, starting with fresh NiCl2 solution and histidine-tag TNFα . Conditions to run the 
kinetic study were as follows; flow rate of 30 μ L/min, 200 second contact time for NiCl2 solution (0.4 mL), 250 sec-
ond contact time for human histidine-tag TNFα (5 μ g, 1.0 mL), 150 second contact time for series of infliximab 
solutions (0.2 mg/mL–0.0625 mg/mL), and FpFInfliximab solutions (0.2 mg/mL–0.0625 mg/mL). The NTA chip was 
regenerated using EDTA solution (350 mM, 1.0 mL) for 60 seconds.
Experimental Autoimmune Uveoretinitis (EAU) Induction and therapeutic intervention. 
Female B10.RIII mice were immunized subcutaneously in one flank with 50 μ g RBP-3161–180 in phosphate buffered 
saline (PBS) emulsified with Complete Freund’s Adjuvant (CFA) supplemented with 1.5 mg/ml Mycobacterium 
tuberculosis complete H37 Ra (BD Biosciences, Oxford, UK) (1:1 vol/vol). The mice also received 1 μ g Bordetella 
pertussis toxin (Tocris, Bristol, UK) intraperitoneally (i.p.).
For local administration of infliximab or FpFinfliximab, intravitreal injections were performed on day 10 
post-immunization. In brief, the eye was proptosed and held in position with a pair of forceps, while 15 μ g of 
infliximab or FpFinfliximab diluted in 2 μ l PBS was injected using a 33-gauge hypodermic needle (Esslab, Essex, UK). 
The injection site was treated with chloramphenicol and globe reposited.
EAU Clinical Assessment. Using a method adapted from Paques et al.54 an endoscope with a 5 cm long 
teleotoscope of 3 mm outer diameter (1218AA; Karl Storz, Tuttlingen, Germany) was connected to a Nikon D80 
digital camera with a 10-million pixel charge-coupled device image sensor and Nikkor AF 85/F1.8 D objective 
(Nikon, Tokyo, Japan), with an additional + 4.00 dioptre magnifying lens. Through pupils dilated with topical 
tropicamide 1% and phenylepherine 2.5% (Minims, from Chauvin Pharmaceuticals, UK), and topical oxybro-
pucaine 0.4% (Minims) and Viscotears (Novartis Pharmaceuticals, UK) for corneal anesthesia, images were 
obtained by direct corneal contact with the endoscope. Images were processed using Adobe Photoshop (Adobe 
Corporation, Mountain View, CA). Using an adapted clinical grading system, fundal images were scored accord-
ing to inflammatory changes to the optic disc and retinal vessels in addition to retinal lesions and structural 
damage24. All scores were added together to calculate a final disease score.
Isolation and flow cytometric assessment of retinal infiltrate. Each eye was dissected in 100 μ l 
ice-cold HBSS with aqueous, vitreous and retina extracted using a limbal incision, lens extraction and transfer 
into a 1.5 mL tube. The tissue was mechanically dissociated by rapping the tube across a standard rack ten times 
before transfer into a 96-well 60 μ m cell strainer plate (Merck Millipore, UK). This was centrifuged at 1200 rpm 
for 5 minutes, the retinal supernatants was aspirated and the remaining cell pellet transferred into a 96-well 
V-bottom plate for immuno-staining.
Cells were incubated with 24G2 cell supernatant for 10 minutes at 4 °C before incubation with fluorochrome- 
conjugated monoclonal antibodies against cell surface markers including, CD4 [RM4-5], CD8 [53–6.7], CD11b 
[M1/70], Ly6G [1A8] and CD45 [30-F11] at 4 °C for 20 minutes. Cells were resuspended in 7AAD, and dead cells 
excluded from analysis by gating on 7AAD negative cells. Cell suspensions were acquired using a 3-laser BDTM 
LSR-II flow cytometer (BD Cytometry Systems, Oxford, UK). Analysis was performed using FlowJo software 
(Treestar, San Carlos, California). Cell numbers were calculated by reference to a known cell–standard, as pre-
viously reported55. Briefly, splenocytes at a range of known cell concentrations were acquired using a fixed and 
stable flow rate for 1 minute. Based on total cell number acquired during this time, a standard curve was generated 
and used to interpolate cell concentrations of ocular infiltrating cells acquired at the same flow rate and time.
Cell culture and intracellular uptake assay. A spontaneously transformed mouse retinal pigment epi-
thelium (RPE) cell line B6-RPE0731 was cultured in DMEM medium supplemented with 10% heat-inactivated 
fetal calf serum, 2% L-glutamine, 1 mM sodium pyruvate, 60 μ M 2-mercaptoethanol, 100 U/ml penicillin and 
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100 μ g/ml streptomycin (complete medium) at 37 °C in an atmosphere of 5% CO2. RPE cells were passaged with 
a split ratio of 1:5 using 0.05% trypsin-EDTA (Life Technologies, Paisley, UK), and allowed to recover for 2 days 
in complete medium prior to experiments.
Confluent monolayers of B6RPE-07 cells in 24-well plates were treated once with 250 μ g infliximab or 
FpFinfliximab for 4 or 24 hrs. Following treatment, B6RPE-07 cells were washed twice with ice-cold PBS. Cells were 
lysed directly from the plate using 200 μl CelLytic M solution supplemented with protease inhibitor cocktail 
(both from Sigma), and incubated on ice with gentle shaking for 10 minutes. Finally, these whole cell lysates were 
centrifuged for 10 minutes, at 4 °C at 13,000 rpm and the supernatant lysate collected and stored at − 80 °C. To 
ensure equal loadings, a bicinchoninic acid (BCA) protein assay was performed prior to SDS-PAGE, and samples 
prepared with 5× Laemilli buffer. For Western blot, 10 μ g of cell lysate loaded per well and separated on a 8–16% 
SDS-PAGE gel (Biorad), and proteins transferred to a nitrocellulose membrane. Following blocking in 5% milk/
TBS/Tween-20, the membrane was subjected to analysis using the anti-human IgG (Fab specific)-peroxidase 
antibody (1:1000) (A0293; Sigma) and β -actin antibody (Cell Signaling) followed by a HRP conjugated polyclonal 
anti-mouse IgG (1:2000) before visualization using the chemiluminescent method (GE Healthcare Life Sciences).
Total RNA from B6RPE-07 cells, and ex-vivo mouse retina and corneal tissue was isolated using TRIzol rea-
gent (Life Technologies), treated with RQ1 RNase-free DNase before cDNA synthesis using the ImProm-IITM 
Reverse Transcription System (Promega, Southampton, UK). cDNA was amplified using the Power SYBR® Green 
PCR Master Mix Reagent (Life Technologies) on a StepOne™ Applied Biosystems Real-Time PCR System. Mouse 
primer sequences used were: Fcgrt F: AGCTCAAGTTCCGATTCCTG; R: GATCTGGCTGATGAATC29; Gapdh 
F: TTCACCACCATGGAGAAGGC; R: GGCATGGACTGTGGTCATGA.
Statistical analyses. Data was analyzed with unpaired Student’s t-test (GraphPad Prism software, San 
Diego, CA). Data are generated as mean ± SEM and representative of at least 2 independent experiments. Values 
were considered statistically significant at *p < 0.05, **p < 0.005, ***p < 0.0005.
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